The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence

被引：11

作者：

McIntyre, Roger S. ^{[1
,2
,3
,4
]}

Rodrigues, Nelson B. ^{[1
,2
,3
]}

Lipsitz, Orly ^{[1
,2
,3
]}

Nasri, Flora ^{[1
,2
]}

Gill, Hartej ^{[1
,2
,3
]}

Lui, Leanna M. W. ^{[1
,2
]}

Subramaniapillai, Mehala ^{[1
,2
,3
]}

Kratiuk, Kevin ^{[3
]}

Teopiz, Kayla ^{[3
]}

Ho, Roger ^{[5
]}

Lee, Yena ^{[1
,2
,3
]}

Mansur, Rodrigo B. ^{[1
,2
]}

Rosenblat, Joshua D. ^{[1
,2
,3
,4
]}

机构：

[1] Univ Hlth Network, Mood Disorders Psychopharmacol Unit, 399 Bathurst St,MP 9-325, Toronto, ON M5T 2S8, Canada

[2] Univ Toronto, Toronto, ON, Canada

[3] Canadian Rapid Treatment Ctr Excellence, Mississauga, ON, Canada

[4] Brain & Cognit Discovery Fdn, Toronto, ON, Canada

[5] Natl Univ Singapore, Dept Psychol Med, Singapore, Singapore

来源：

JOURNAL OF PSYCHOPHARMACOLOGY | 2021年 / 35卷 / 02期

基金：

加拿大健康研究院;

关键词：

Ketamine; treatment-resistant depression; major depressive disorder; bipolar disorder; anxiety; distress; SUICIDAL IDEATION; ANTIDEPRESSANT; SYMPTOMS; INFUSION;

D O I：

10.1177/0269881120954048

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Individuals meeting criteria for treatment-resistant depression (TRD) are differentially affected by high levels of anxiety symptoms. Aims: There is a need to identify the efficacy of novel rapid-onset treatments in adults with mood disorders and comorbid anxious-distress. Methods: This study included patients with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) who were receiving intravenous (IV) ketamine treatment at a community-based clinic.Anxious-distress was proxied using items from the Quick Inventory of Depressive Symptomatology-Self Report 16-item (QIDS-SR16) and Generalized Anxiety Disorder 7-item (GAD7) scales. The difference in QIDS-SR(16)total score, QIDS-SR(16)suicidal ideation (SI) item and GAD7 score were analyzed between groups. Results: A total of 209 adults with MDD (n= 177) and BD (n= 26) were included in this analysis. From this sample, 94 patients (mean = 45 +/- 13.9 years) met the criteria for anxious-distress. Individuals meeting the criteria for anxious-distress exhibited a significantly greater reduction in QIDS-SR(16)total score following four infusions (p= 0.02) when compared with patients not meeting the anxious-distress criteria. Both anxious-distressed and low-anxiety patients exhibited a significant reduction in SI (p< 0.0001) following four infusions.Finally, there was a significantly greater reduction in anxiety symptoms in the anxious-distress group compared with the non-anxious distress group following three (p= 0.02) and four infusions (p< 0.001). Conclusion: Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms.

引用

页码：128 / 136

页数：9

共 30 条

[1] Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression [J].

aan het Rot, Marije ;

Collins, Katherine A. ;

Murrough, James W. ;

Perez, Andrew M. ;

Reich, David L. ;

Charney, Dennis S. ;

Mathew, Sanjay J. .

BIOLOGICAL PSYCHIATRY, 2010, 67 (02) :139-145

[2] Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression [J].

Albott, C. Sophia ;

Lim, Kelvin O. ;

Forbes, Miriam K. ;

Erbes, Christopher ;

Tye, Susanna J. ;

Grabowski, John G. ;

Thuras, Paul ;

Batres-y-Carr, Tegan M. ;

Wels, Joseph ;

Shiroma, Paulo R. .

JOURNAL OF CLINICAL PSYCHIATRY, 2018, 79 (03)

[3]

American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), V5th, DOI DOI 10.1176/APPI.BOOKS.9780890425596

[4] Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety [J].